Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AZD8630 Device Transition in Healthy Volunteers
NCT06531811Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azd8630 in asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: Area under the serum concentration-time curve from time zero to the last quantifiable concentration at Day 11. Started Aug 2024; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06531811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531811.